immuno-oncology

News

Astellas taps GO's glycoprotein platform with $783.5m deal

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targ

News

Targeting COVID-19 and cancer with immunotherapy advancements

RhoVac pummelled as lead cancer vaccine fails study

Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate

News

BMS' Opdivo gets late-stage oesophageal cancer nod from FDA

The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb's PD-1 inhibitor Opdivo for previously-untreated advanced oesophageal cancer, encroaching on territory held b

News

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Johnson & Johnson and Legend Biotech will arrive at next week's ASCO congress with a new EU approval for multiple myeloma CAR-T Carvykti.

News

Bayer bails on $670m CAR-T partnership with Atara

In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death.

News

Close-up image of a firm handshake between two colleagues

Merck snaps up cancer drug from China's Kelun in $1.4bn deal

Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China's Sichuan Kelun Pharmaceutical, and is keeping the details close to its chest.

Astellas taps GO's glycoprotein platform with $783.5m deal

RhoVac pummelled as lead cancer vaccine fails study

BMS' Opdivo gets late-stage oesophageal cancer nod from FDA

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Bayer bails on $670m CAR-T partnership with Atara

Merck snaps up cancer drug from China's Kelun in $1.4bn deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

immuno-oncology

Editor's Picks